Therapy Areas: Autoimmune
Hemogenyx reports positive safety and early efficacy data from third patient in CAR-T trial
17 September 2025 - Biopharmaceutical group Hemogenyx Pharmaceuticals plc (LSE: HEMO) confirmed on Wednesday that the third patient in its Phase I clinical trial of HG-CT-1 CAR-T therapy for relapsed/...
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
15 September 2025 - Biopharmaceutical company Forte Biosciences Inc (NASDAQ: FBRX) on Monday reported additional data from its Phase 1b trial of FB102 in celiac disease, presented at the Tampere Celia...
Hemogenyx Pharmaceuticals partners with Made Scientific to advance CAR-T therapy
8 September 2025 - Biopharmaceutical group Hemogenyx Pharmaceuticals plc (LSE: HEMO) announced on Monday that it has entered a manufacturing partnership with US-based contract development and manufact...
Onco3R Therapeutics receives Belgian regulatory approval for clinical trial of novel SIK3 inhibitor
5 September 2025 - Onco3R Therapeutics, a Belgium-based clinical-stage immunology and oncology biotech company, announced on Thursday the approval of a clinical trial application by the Belgian regula...
ImmuPharma files patent for P140 'Immunormalizer' with precision diagnostic for autoimmune diseases
1 September 2025 - Biopharmaceutical company ImmuPharma PLC (LSE: IMM) announced on Monday that it has filed a new patent application covering its lead asset P140, described as the world's first ...
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
25 August 2025 - Biotechnology company Coya Therapeutics Inc (NASDAQ: COYA) announced on Monday that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) applica...